NCT05912296View on ClinicalTrials.gov

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

March 4, 2025

Study Completion Date

March 31, 2025

Conditions
Hyperlipemia
Interventions
DRUG

RBD7022

Subcutaneously Administered RBD7022 in Healthy Subjects.

DRUG

RBD7022

Subcutaneously Administered RBD7022 in Healthy Subjects.

DRUG

Placebo

Subcutaneously Administered Placebo in Healthys Subject.

DRUG

Placebo

Subcutaneously Administered Placebo in Healthys Subject.

Trial Locations (1)

010

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY

NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 | Biotech Hunter | Biotech Hunter